Stay updated on Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial
Sign up to get notified when there's something new on the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page.

Latest updates to the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange Detected- The page revision was updated from v3.2.0 to v3.3.2. This update does not appear to alter study details or other user-facing content.SummaryDifference0.1%

- Check28 days agoChange DetectedDeletion of the general government funding status notice that warned about potential updates and directed users to cc.nih.gov and opm.gov for operating status updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check42 days agoChange DetectedThe update appears to be cosmetic UI/layout changes with no changes to the study's core details such as title, conditions, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference4%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page.